---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027101"
form_type: "8-K"
ticker: "NSPR"
cik: "0001433607"
company_name: "InspireMD, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:28:31.042457+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# InspireMD reports Q2 revenue up 9.6% to $1.65M; secures up to $113.6M private placement

## Summary
- Closed transformational private placement: $42.2M upfront, up to $71.4M additional on milestone warrants.
- Completed enrollment in C-Guardians IDE trial; anticipates PMA submission in H2 2024.
- Q2 CGuard EPS revenue $1.65M (+9.6% YoY); units sold 2,804 (+7.8% YoY).
- Net loss $5.08M ($0.24 per share) vs $4.64M ($0.59) in Q2 2022.
- Cash $47M as of June 30, up from $17.8M at Dec 31, 2022.

## SEC filing metadata
- accession: 0001493152-23-027101
- form_type: 8-K
- ticker: NSPR
- cik: 0001433607
- company_name: InspireMD, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1433607/000149315223027101/0001493152-23-027101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1433607/000149315223027101/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027101
- JSON: https://secwatch.observer/filing/0001493152-23-027101.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027101.txt

## Key facts
- Earnings Releases
  InspireMD, Inc. reported the six months ended June 30, 2023 results: revenue $2,888,000, net income $9,333,000, EPS $0.64 per basic and diluted share.
  - Period: the six months ended June 30, 2023
  - Revenue: $2,888,000
  - Net income: $9,333,000
  - EPS: $0.64 per basic and diluted share
  - Result: reported results
  source text: after deducting transaction expenses. Financial Results for the Six Months ended June 30, 2023 For the six months ended June 30, 2023, revenue increased by $174,000, or 6.4%, to $2,888,000, from $2,714,000 during the six months ended June 30, 2022. This increase was predominantly driven by a 8.3% increase in sales volume of CGuard EPS from $2,666,000 during the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1433607/000149315223027101/0001493152-23-027101-index.htm
- Earnings Releases
  InspireMD, Inc. reported the three months ended June 30, 2023 results: revenue $1,649,000, net income $5,077,000, EPS $0.24 per basic and diluted share.
  - Period: the three months ended June 30, 2023
  - Revenue: $1,649,000
  - Net income: $5,077,000
  - EPS: $0.24 per basic and diluted share
  - Result: reported results
  source text: performed with its CGuard Prime CAS stent delivery platform as part of C-Guardians trial enrollment. ● Generated record CGuard revenue for the second quarter 2023 of $1,649,000, a 9.6 % increase over the same period in 2022 and a 33% increase over the first quarter of 2023. ● Sold 2,804 CGuard EPS stent systems in the second quarter of 2023, as compared
  evidence_url: https://www.sec.gov/Archives/edgar/data/1433607/000149315223027101/0001493152-23-027101-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.